Autopsy report · NCT01458548

Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)

“This study had an major amendment in 12/2006 introducing risk stratified sequential treatment (RSST). The modified protocol is registered with NCT00590447.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 years 10 months after it had already started.
• Ran for about 8 years 10 months before it stopped.
• 70 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Charite University, Berlin, Germany

Sponsor type

University, hospital or other

Conditions

Post-transplantation Lymphoproliferative Disorder

Interventions

Rituximab; CHOP

Participants

70

Sites

4

Countries

Australia, France, Germany, Sweden

Trials that died the same way

• Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease
  “Per protocol, 3 sequential dose cohorts were planned. Study discontinued by Sponsor based upon serious adverse events in first 2 of 3 participants in Cohort 1.” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.